CRSP - Vertex unit ViaCyte opts out of CRISPR diabetes program
2024-01-08 15:36:52 ET
More on CRISPR Therapeutics
- CRISPR Therapeutics: Therapies Of The Future Are Almost Here, But Not Yet
- Crispr Therapeutics Is Overvalued (Rating Downgrade)
- Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed
- CRISPR, bluebird stocks slide as Agios rallies on thalassemia study
- Another CRISPR approval not likely 'any time soon' - report
For further details see:
Vertex unit ViaCyte opts out of CRISPR diabetes program